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Abstract
Background: In recent years, growing interest in the neuropsychology of bipolar disorder has emerged, giving rise to the accumulation of a robust body of 
evidence on this topic and to several related questions. Objective: To provide a state-of-the-art overview of the neuropsychological profile of bipolar disorder. 
Method: A thorough literature search was performed. Published research evidence was summarized and organized along three key pathways: findings from 
cross-sectional studies of cognition in bipolar patients, cognitive heterogeneity among affected subjects, and trajectory of neuropsychological deficits. Results: 
At least two thirds of bipolar patients display neuropsychological deficits, even in euthymia. Although bipolar disorder was found to be associated with an 
increased risk of dementia, data from elderly subjects and longitudinal research do not support a worsening of cognitive performance over time. Discussion: 
Cognitive dysfunctions are part of the clinical conceptualization of bipolar illness. However, they may not be present in all affected subjects and their course 
appears to be stable in most cases. Available evidence may be highlighting the fact that bipolar disorder is characterized by remarkable heterogeneity regar-
ding cognitive outcomes. Different variables may be related to such heterogeneity and should be the focus of therapeutic approaches and further research. 
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Introduction
Bipolar disorder (BD) is a complex chronic illness that affects mood 
and biological rhythms, causing subtle to severe distortions of normal 
behavior. BD is associated with significant functional impairment, 
even when appropriately treated and after symptomatic recovery is 
achieved1,2.
Poor functional outcomes have been shown to be strongly as-
sociated with persistent neuropsychological deficits3-5, which are cur-
rently acknowledged as an important feature of BD. Indeed, during 
the last decade, the long-held assumption of cognitive indemnity of 
BD was debunked as a result of compelling evidence for conspicuous 
cognitive deficits in a significant percentage of affected subjects, even 
during periods of euthymia6. Notwithstanding the release of copious 
amounts of research reports on this topic, the neuropsychological 
profile of the disorder remains unclear, and several related questions 
have arisen in the last few years.
The aim of this study was to integrate the pieces of evidence 
gathered at present in order to provide an updated review on cogni-
tive functioning in BD. The most controversial issues related to this 
subject were discussed, and targets for forthcoming research were 
highlighted. 
Methods
First, an extensive computerized literature search was performed. 
Articles available with an abstract in English were retrieved from 
electronic databases (PubMed, PsychINFO, SciELO, and Lilacs), 
covering the period from January 1990 to August 2015. Afterwards, a 
narrative review was conducted, giving special consideration to large 
studies, systematic reviews, and, particularly, to meta-analyses, as the 
last allow for more precise estimates of effect magnitude than data 
derived from primary studies. In order to provide a comprehensive 
framework, the currently available evidence on neuropsychological 
functioning in BD was summarized and organized around three key 
topics: 1) neuropsychological profile of BD patients; 2) cognitive 
heterogeneity among bipolar subjects; and 3) longitudinal trajectory 
of cognitive deficits in BD. 
Results
Neuropsychological profile of BD
In order to characterize a BD profile of neuropsychological perfor-
mance, findings from both subjects in the premorbid phase of the 
disorder and patients with established illness are exhibited (Table 1). 
Among the latter, the findings of studies on subjects belonging to 
different age groups are reviewed. 
Findings in the premorbid phase of BD 
Neurocognitive functioning in the premorbid phase of the illness 
has been appraised by means of three methodologies: prospective 
conscript studies, evidence from birth cohorts and at-risk subjects 
followed longitudinally. Martino et al.7 reviewed the findings from 
these approaches and reported that with the exception of one study8, 
which showed that poor performance on visuospatial reasoning and 
increased performance on the arithmetic subtest were associated with 
BD, studies failed to find any differences between people who were 
subsequently diagnosed with BD and healthy controls on measures 
of general intelligence9-11. In keeping, Trotta et al.12, in a meta-analysis 
of four prospective cohort studies, yielded a nonsignificant overall 
effect size for premorbid IQ in BD. 
However, these studies assessed general intellectual function and 
not specific cognitive domains. Findings regarding the latter are scant 
so far. Meyer et al.13 used data from a 23-year longitudinal prospec-
tive study of offspring of mothers with BD, unipolar depression or 
no history of BD (n = 74). They were evaluated from 8 to 15 years 
with general intelligence tests, from 11 to 19 years with executive 
functions measures and as young adults with psychopathology mea-
sures (SCID-I). Offspring who were later diagnosed with BD during 
adulthood (n = 9) had lower performance than healthy controls on 
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measures of executive functions with moderate-large effect sizes 
(d = 0.58-1.34) at age 11-19, although they had comparable IQ when 
they were 8-15 years old. Ratheesh et al.14 followed a cohort of 413 
children who were at ultra-high risk for psychosis for a mean period 
of 8.2 years. Children who were later diagnosed with BD showed 
lower performance than healthy controls on measures of global intel-
ligence, visuospatial ability and executive function with large effect 
sizes (d = 1.35-1.56). In keeping, Klimes-Dougan et al.15 conducted 
an extensive neuropsychological assessment of adolescent children of 
mothers with a history of BD (n = 43) or major depressive disorder 
(n = 72). They found that offspring of mothers with BD had poorer 
performance on the Wisconsin Card Sorting Test, which remained 
significant after adjusting for IQ and depressive/manic symptoms.
Findings in pediatric and adolescent patients
A systematic review on cognitive performance in pediatric BD 
patients16 reported that significant deficits in verbal/visual-spatial 
memory, processing speed, working memory and social cognition 
were found quite consistently across the primary studies included. 
Furthermore, two previous meta-analyses showed moderate deficits 
(d = 0.5-0.8) in verbal memory, attention, processing speed and 
executive domains among pediatric and adolescent patients17,18. 
However, most of the primary studies included in these reviews 
were performed during affective episodes. Data on euthymic BD 
pediatric patients are very scant so far. At the primary study level, the 
largest study evaluating cognitive impairments in pediatric bipolar 
patients included 28 unmedicated patients during manic episode, 
medicated euthymic patients (n = 28) and healthy individuals (n = 
28)19. Both patient groups (mean age = 11.74, SD = 2.99) showed large 
(d ≥ 0.8) impairments in domains of attention, executive functions, 
working memory and verbal memory compared to healthy controls. 
However, half of the patients in each group had comorbid ADHD, 
which made it difficult to identify deficits specific to pediatric BD.
Findings in young and middle-aged adults
Aggregate data meta-analyses of neurocognitive functioning in young 
and middle-aged adults20-26 have reported moderate (d = 0.5-0.8) and 
large (d > 0.8) deficits across executive functions, verbal memory, 
attention and processing speed. However, the only individual pa-
tient data meta-analysis of cognition in BD (n = 2876) conducted at 
present27 showed small-to-moderate deficits (d = 0.26-0.63) in most 
neurocognitive domains after controlling for age, premorbid IQ and 
gender. Furthermore, this study reported a large degree of heteroge-
neity across studies, which may explain some differences observed 
in the effect sizes yielded by previous meta-analyses. 
Kurtz and Gerraty25 performed a meta-analysis evaluating the 
profile of neurocognitive impairment of BD patients and the im-
pact of clinical episodes on those measures. The study combined 
results from 42 studies conducted in euthymic patients, 13 studies 
in manic/mixed phase and 5 studies of patients in a depressed state, 
suggesting that, although present during euthymia, a subset of these 
neurocognitive impairments would worsen during periods of acute 
affective episodes. 
With regard to social cognitive domains, evidence for impaired 
emotion recognition and theory of mind in the three phases of BD 
is rather consistent across studies28. A recent meta-analysis of social 
cognition in euthymic bipolar patients29 showed no significant 
patient-control differences for the recognition of three basic emotions 
(happiness, sadness, and anger) whereas small but significant effect 
sizes favoring healthy controls (d < 0.5) were noted for emotional 
intelligence, the Hinting Task, the Eyes Test, and the recognition of 
fear, disgust, and surprise. Furthermore, this study showed a medium 
effect size of impairment (d = 0.58) for the Faux Pas Test. However, 
it is not yet clear whether these social cognitive flaws are epiphe-
nomena of neurocognitive deficits. Finally, the only meta-analysis of 
studies assessing decision-making in samples composed exclusively 
of euthymic subjects30 reported no significant differences between 
controls and patients in the total net score of the Iowa Gambling 
Task. In contrast, primary studies of subjects during acute episodes 
revealed suboptimal task performance31,32 particularly during mania, 
suggesting that decision-making impairments are state-dependent 
in BD patients. 
Findings in elderly adults 
The only meta-analysis of neurocognition in late-life BD33 revealed 
moderate impairments for the cognitive variables analyzed, except for 
phonemic fluency (d = 0.80) and cognitive flexibility (d = 0.88). This 
report took into account the fact that older adults with BD constitute a 
heterogeneous population composed by both people with early-onset 
BD (EOBD), who developed their illness during adolescence/young 
adulthood, and people with late-onset BD (LOBD), who experienced 
their first affective episode at the age of 40 or over. These two sub-
groups may have different features. Typically, patients with LOBD 
show a weaker family history of affective disorders, higher frequency 
of neurological comorbidities, higher cardiovascular risk burden34-36 
and worst neuropsychological performance on almost all measures37, 
suggesting a high influence of non-genetic etiological factors on this 
subgroup of patients. So, when meta-analysis was performed after 
removing the data from LOBD subjects and overall effect sizes were 
recalculated, estimates became much smaller33. A subsequent study38 
showed that euthymic, non-demented elderly patients with BD per-
formed worse than healthy controls on a verbal fluency test (semantic 
fluency-animal naming) with a large magnitude of impairment (d = 
0.86). Furthermore, this study revealed that demented BD subjects 
had a significantly worse performance on the Clock Drawing Test as 
compared with patients with dementia due to Alzheimer’s disease. 
Cognitive heterogeneity among subjects with BD
A recent study by Martino et al.39 showed that 30% of a sample of 100 
BD patients was indistinguishable from healthy subjects in terms of 
cognitive functioning, whereas another 30% displayed more severe 
cognitive deficits than usually reported in the literature (d = 1.13). 
These findings are in keeping with other studies indicating that the 
prevalence of patients without clinically significant cognitive im-
pairment fluctuates between 43% and 70%40-44. Such results may be 
suggesting that primary studies and meta-analyses reporting mean 
values of neurocognitive functioning in BD patients might be failing 
to recognize that a subgroup of patients is demonstrating most of 
the impairment: while some patients might have a neurocognitive 
functioning within normal limits, others might show poorer perfor-
mance than usually reported.  
Longitudinal course of cognitive deficits in BD
In order to evaluate longitudinal trajectories of cognitive deficits in 
patients with BD, four strategies were considered: studies of cogni-
tive performance after first affective episode, longitudinal follow-up 
studies of cognitive functioning, data from patients with long illness 
duration, and evolution to dementia in subjects with BD (Table 2). 
Cognitive functioning in the first episode of BD
Martino et al.7 reviewed 14 studies of cognitive performance in first-
episode patients, and reported that impairments in verbal memory, 
attention, and executive functions tended to be present during and 
after the first episode of the disorder. Considering only studies that 
evaluated patients during euthymia, after recovery of their first 
manic episode, Nehra et al.45 found impairments in IQ, executive 
functions, verbal memory and attention with large effect sizes for 
all measures. Torres et al.46 reported that patients with BD did not 
differ from controls with regard to premorbid IQ and attention, while 
moderate effect size impairments in executive functions, working 
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Table 1. Meta-analyses of cognitive functioning in BD
Meta- analysis Study population Mood state Resultsa
Arts et al. (2008)22 Adult patients and FDR Euthymia BD: Large effect sizes for executive functions and verbal memory 
Medium effect sizes for processing speed and sustained attention
Small effect sizes for visuoperception 
FDR: small, but significant, effect sizes across cognitive domains
Bora et al. (2009)23 Adult patients and FDR Euthymia BD: Moderate-to-large effect sizes for executive functions, sustained 
attention and verbal memory
FDR: small, but significant, effect sizes across cognitive domains
Bora et al. (2011)24 Adult patients Euthymia and depression 
(mixed sample)
Small-to-moderate effect sizes across all domains (BD II-only vs. 
controls) 
BD II less impaired than BD I on memory measures 
Bora and Pantelis (2015)49 FEBD Euthymia and mood episodes 
(mixed sample)
Moderate effect sizes for attention, processing speed, verbal and visual 
memory. Small effect sizes for most executive domains
Bourne et al. (2013)27 Adult patients Euthymia Small-to-moderate effect sizes for verbal memory, executive functions 
and sustained attention 
Garcia Nieto and Castellanos 
(2011)18
Pediatric patients Euthymia and mood episodes 
(mixed sample)
Moderate effect sizes for verbal memory, attention, processing speed 
and executive domains
Joseph et al. (2008)17 Pediatric patients Euthymia and mood episodes 
(mixed sample)
Moderate-to-large effects for verbal memory, attention, executive 
functions, working memory and verbal fluency. Small effects for IQ and 
motor speed 
Kurtz and Gerraty (2009)25 Adult patients Euthymia
Manic episode 
Depressive episode
Euthymia: moderate effect sizes for attention, delayed memory and 
executive functions. Large effect sizes for verbal learning 
Depressive and manic episodes: more severe impairment in verbal 
learning and phonemic fluency
Lee et al. (2014)48 FEBD Euthymia and manic episode Medium-to-large deficits for psychomotor speed, attention, working 
memory and cognitive flexibility 
Small deficits for verbal learning and memory, attentional switching, 
and verbal fluency. Medium-to-large deficit for response inhibition only 
detected in non-euthymic cases
Mann-Wrobel et al. (2011)26 Adult patients Euthymia Moderate-to-large effect sizes across all domains
Robinson et al. (2006)20 Adult patients Euthymia Large effect sizes for executive function and verbal learning. Medium 
effect sizes for delayed recall, set-shifting, processing speed, sustained 
attention and response inhibition. Small effect sizes for verbal fluency
Torres et al. (2007)21 Adult patients Euthymia Medium-to-large impairment for executive functions, attention, 
processing speed and episodic memory 
Trotta et al (2015)12 Subjects in the premorbid 
stage of illness
Euthymia Non-significant overall effect size for IQ between subjects who 
subsequently developed BD and those who did not develop any 
disorder
Samamé et al. (2012)30 Adult patients Euthymia Non-significant overall effect size for decision-making (Iowa Gambling 
Task). Small effect size for facial emotion recognition. Moderate effect 
sizes for mentalizing domains
Samamé et al. (2013)33 Elderly patients Euthymia Non-significant differences for the MMSE and CDT. Moderate effect 
sizes for sustained attention, digit span, delayed recall, verbal fluency 
and cognitive flexibility
Samamé et al. (2015)29 Adult patients Euthymia Medium effect size for the Faux-Pas test. Non-significant differences 
for the recognition of three emotions (happiness, anger and sadness). 
Small effect size for the recognition of surprise, fear and disgust, 
emotional intelligence and the Hinting task
a All effect sizes favor healthy controls.
BD: bipolar disorder; FDR: first degree relatives; FEBD: first episode bipolar disorder; MMSE: Mini-Mental State Examination; CDT: Clock Drawing Test. 
memory and visual reasoning were found. Finally, López-Jaramillo 
et al.47 showed that patients with BD performed worse than healthy 
controls on a measure of working memory with moderate effect size, 
without between-group differences for IQ, verbal memory, attention, 
processing speed and executive functions. These results are in line 
with two recent meta-analyses of cognitive functioning in BD pa-
tients after their first affective episode48,49, which showed widespread 
impairment. According to these quantitative reviews, the severity of 
impairment was generally comparable to that found in studies with 
patients after recurring episodes, with medium effect sizes for most 
neuropsychological variables. 
However, another systematic review50 reported that BD patients 
in remission immediately after first manic episode did not display 
deficits in non-verbal memory and verbal fluency, whereas evidence 
for impairments in other neurocognitive domains was inconsistent 
across reports, with most studies revealing negative findings, except 
for working memory.  
Longitudinal studies
The only meta-analysis summarizing the results of longitudinal 
studies of euthymic adults with BD did not show any significant dif-
ferences between BD patients’ performance at baseline and healthy 
controls after a mean follow-up period of 4.62 years for 14 cognitive 
variables51. In this line, a recent study analyzed the one-year trajectory 
of cognitive deficits in recently diagnosed BD and reported an im-
provement in processing speed and executive functions52. Similarly, 
Santos et al.53 found no differences in neuropsychological trajectory 
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between patients and healthy controls after 5 years follow-up of a large 
sample of BD subjects. Another recent study followed prospectively 
a cohort of 71 major depressive disorder, 61 BD and 35 schizophre-
nia patients, evaluated at baseline and after a mean of 20.6 months. 
The authors reported that, as a group, BD displayed stable cognitive 
functioning and even improved on a measure of verbal memory54. 
However, there are a number of limitations to be considered when 
analyzing these data. First, follow-up periods were relatively short in 
most studies and it should not be assumed that no cognitive decline 
occurred after this period. Another important limitation was that 
not all studies controlled for mood symptomatology at baseline and 
during follow-up. Therefore, changes in mood state could have in-
fluenced the results. Finally, longitudinal studies available at present 
only explored the trajectory of cognitive functioning in full-blown 
BD, whereas the course of cognition in the period comprised between 
the premorbid stage of the disorder and the onset of mood symptoms 
remains unexplored. 
Patients with long illness duration 
Studies of cognitive performance in elderly patients with BD tended 
to find the same pattern of cognitive deficits both in terms of domain 
affected and magnitude reported in younger patients, suggesting 
indirectly no neurocognitive progression of the illness33. In order to 
assess the potential effect of illness progression on neurocognition, a 
study compared neurocognitive functioning between patients aged 40 
years or younger (Y-BD) and patients aged 60 years or older (E-BD). 
Despite E-BD patients having illness duration almost four times lon-
ger than Y-BD patients, no significant differences in neurocognitive 
functioning were found between these two groups55.
A possible limitation of these studies is selection bias in samples 
of elderly BD patients, since those who developed dementia or severe 
cognitive impairment, might have been institutionalized or dead and 
therefore under-represented.
Evolution to dementia
Some small pioneering studies of non-euthymic bipolar elders found 
that a high percentage of them scored positively on screening tests 
for dementia56,57. In accordance with these findings, evidence from 
population-based studies showed that the diagnosis of BD was sig-
nificantly associated with an increased risk of dementia58,59.
These results indicate that overall, there seems to be a percentage 
of people with BD that will develop dementia. However, this outcome 
may be present in around 6-9% of BD patients included. Taking this 
into account, dementia might be an infrequent outcome rather than 
the average evolution of BD6. 
Discussion 
In this study, the available evidence on the neuropsychological profile 
of BD was reviewed in order to address some of the controversies 
regarding this matter. Our findings indicate that cognitive deficits 
are present in a significant percentage of affected subjects, even 
during euthymia periods and that they seem to exacerbate during 
acute mood episodes. Such impairments could be present prior to 
illness onset, and are evident in BD patients belonging to different 
age groups. Furthermore, some findings suggest that the magnitude 
of these deficits would be similar in young and elderly patients. 
These results are in line with preliminary findings from longitudinal 
studies, which do not reveal any changes in the neuropsychological 
performance of BD subjects over time. 
At present, there appears to be a certain degree of agreement in 
the fact that neuropsychological performance is a major determinant 
of functional outcomes in BD patients. As shown in this review, 
although it is widely acknowledged that bipolar subjects exhibit 
neurocognitive impairments in domains of verbal memory, atten-
tion and executive functions, among others, the notion of cognitive 
impairment may not be applicable to all patients40,60. This cognitive 
heterogeneity might be explained by a number of environmental and 
genetic causes reported in the literature to alter normal cognitive 
functioning in BD patients such as obstetric complications61, genetic 
polymorphisms62, childhood trauma63, infection with Herpes Sim-
plex virus type 164,65, comorbidity with anxiety disorder66 or alcohol 
abuse67-69, age at onset37,70, subclinical hypothyroidism71 and exposure 
to antipsychotics72,73.
Beyond the well-documented relationship between cognitive and 
functional outcomes in BD, another variable that has been tradition-
ally associated with cognitive performance is the number of previous 
episodes, especially manic ones74,75. This finding has led some authors 
to suggest a progressively deteriorating nature of cognitive deficits 
in BD. However, these data derive from cross-sectional studies, 
and therefore, the direction of causality cannot be ascertained. In 
fact, a recent prospective study76 found that patients with clinically 
significant cognitive deficits had an increased risk of suffering any 
recurrence and suggested that severe cognitive impairment may be 
the cause, rather than the consequence, of a poorer course of illness, 
thus providing an alternative explanation to this relationship. This 
result may also be suggesting that the subgroups of patients with 
better clinical outcomes and with preserved cognitive function might 
overlap. Hence, the importance of this finding lies in the fact that 
cognitive heterogeneity might be a clue to explain the variability seen 
in areas like global functioning and course of illness, although the 
mechanisms underlying these associations are a matter of specula-
tion nowadays. For example, patients with poor cognitive function-
ing might have poorer treatment adherence77, poorer response to 
Table 2. Main approaches to the study of the longitudinal course of cognitive deficits in BD
Methodological approach Results Main limitations
Cognitive functioning in first-
episode BD
Inconsistent findings. Both impaired and preserved cognitive 
outcomes have been reported48-50
Small sample sizes
Results potentially confounded by mood symptomatology
Longitudinal research Longitudinal meta-analysis does not show any test-retest 
differences for neurocognitive variables51 
Short follow-up periods 
Few data on healthy controls
Dropout bias 
Results potentially confounded by mood symptomatology
Results only account for the course of cognitive deficits after illness 
onset
Cognitive functioning in long-
standing BD
Meta-analysis of cognition in E-BD subjects shows a pattern and 
magnitude of impairment similar to those reported for young adult 
patients33
Comparison between Y-BD and E-BD reveals no significant 
differences in cognitive performance55
Small sample sizes
Few studies performed on E-BD
BD patients with poor outcomes (dementia, institutionalized) 
probably not included in E-BD samples
Population-based studies An association between BD and an increased risk of dementia is 
supported by available data58,59
These studies reflect the outcome of a minority of BD patients (6%-
9%)
BD: bipolar disorder; E-BD: elderly BD patients (aged 60 years or above); Y-BD: young BD patients (aged 40 years or under). 
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psychoeducation programs and psychotherapeutic interventions 
leading to poorer disease evolution and global functioning. Indeed, 
a previous study noted that cognition was probably a major source 
of uncontrolled variance regarding response to treatment41. 
Despite these considerations, the aforementioned relationship 
between number of episodes and cognitive functioning47,78, together 
with several recent reports showing a tendency towards episode ac-
celeration and the evidence of an increased risk of suffering dementia 
in bipolar subjects, has given rise to the notion of BD as a progres-
sively deteriorating condition and the application of staging models 
to this group of disorders. In the context of the utilization of staging 
conceptualizations for the appraisal of severe psychiatric conditions, 
the term ‘neuroprogression’ has been coined to refer to a pathologi-
cal reorganization of the central nervous system that would occur 
along the course of these illnesses79. Applied to BDs, the hypothesis 
of neuroprogression suggests that different characteristics of the 
disorder follow a progressive path from prodromic to more severe 
and refractory presentations80. However, it has not been adequately 
validated so far and several artifacts must be considered when in-
terpreting the evidence often thought of as being ‘in support’ of this 
notion81. What is more, recent reports have emphatically stated that 
cognitive deficits are progressive in BD on the basis of the findings of 
cross-sectional studies82,83. According to these investigations, patients 
in later stages have worse functional outcome/higher number of 
episodes than subjects in early stages, who display better outcomes. 
Given the strong correlation between functional outcomes and 
cognitive functioning84-86, the finding of a worse neuropsychological 
performance in late-stage patients as defined on the basis of poor 
global functioning is predictable. However, it is not possible to infer 
neuroprogression from this, given that no longitudinal study at pres-
ent has proved that the different presentations of BD are moments in 
the development of the disorder as the utilization of the word “stage” 
would necessarily imply. In fact, taken together, findings evaluating 
long-term evolution of cognitive deficits in BD do not support the 
hypothesis that cognitive deficits tend to worsen over the course of 
illness. Rather, it would be more sensible to conclude in the light of the 
currently available evidence that there are different subgroups within 
the disorder that may have different cognitive trajectories. Indeed, a 
meta-analysis by our group33, revealed that elderly BD subjects, with 
about three decades of illness duration and the longstanding expo-
sure to variables which may negatively impact cognition, displayed 
a magnitude of impairment similar to that observed in young adult 
subjects with BD. Such finding may be indicating that the time being 
ill does not allow for any prediction on the cognitive outcomes nor the 
assumption of an evolving nature of the disorder. Instead, evidence 
available so far may be indicating the existence of different clinical 
subgroups within BD, each having distinct features and cognitive 
trajectories. For example, data regarding evolution to dementia in 
BD suggests that only 6%-9% might have a poorer evolution and 
this malignant outcome. 
Nevertheless, it is not yet possible to conclude from these find-
ings that cognitive deficits are static over the course of BD. On the 
one hand, because the approaches utilized to the study of this issue 
have several methodological limitations. On the other hand, because 
cognitive decline could occur after the emergence of mood symptoms 
or at a preclinical stage and there are no studies assessing cognitive 
function in the same subjects both before and after the onset of the 
disorder. However, as shown in this review, neuropsychological stud-
ies using specific domain tasks, though scant, have not supported the 
hypothesis of preserved cognition in the premorbid stage. In spite of 
this, it could be hypothesized that whereas some patients present with 
cognitive impairment at the moment of their first affective episode, 
some patients do not, resulting in subgroups in terms of cognitive 
performance at the time of illness onset. Indeed, Mac Cabe et al.87 
reported that both low and high grades in high school predicted 
future manic episodes, underscoring heterogeneity in cognitive 
functioning in adolescents prior to receiving a BD diagnosis. Thus, 
the evidence available at present shows that patients in the premorbid 
phase of BD, as a whole, may not present with preserved cognitive 
functioning. However, cognitive outcomes may be heterogeneous 
among these patiens. Such preliminary findings do not support 
the hypothesis of progressive deterioration of cognition either and 
highlight the heterogeneous nature of BD. 
In view of the existing evidence on cognitive functioning in 
BD, targets for future research are proposed. First, further studies 
of euthymic patients and subjects at risk for the disorder are needed 
in order to better clarify the neuropsychological profile of BD. For 
example, it is currently a matter of debate whether BD patients display 
an intermediate performance between subjects with schizophrenia 
and healthy controls or if the neuropsychological profiles of these 
disorders are qualitatively different. Recent preliminary findings 
support the latter notion39,88. Second, large longitudinal studies, 
with long follow-up periods, assessing specific cognitive domains 
in BD patients are clearly needed as well as studies of cognitive 
performance in the same subjects both after and before the onset 
of mood episodes in order to ascertain whether neuropsychological 
deficits worsen over time, and if so, to determine the moment in 
which cognitive decline would occur. Third, a number of variables 
found to be related to poorer cognitive outcomes should be studied 
more deeply. In addition, the relationship between mood episodes 
and cognitive dysfunction (i.e., as inductors of cognitive impairments 
or exacerbating existing cognitive dysfunctions) should be further 
assessed. Insights into cognitive subgroups in BD might also be 
useful. For example, prospective studies evaluating clinical course/
functional outcomes in newly diagnosed patients (i.e. after recovery 
of their first manic episode) or high-risk BD, divided by their cogni-
tive performance might be useful in determining whether cognitive 
performance determines poor clinical outcomes or vice versa.
Therapeutic implications of cognitive impairment in BD
As neuropsychological impairment is currently acknowledged as an 
important target for therapeutic efforts, it is important that clinicians 
are aware of a number of variables that may affect cognitive outcomes.
At present, preclinical findings have suggested that lithium might 
have beneficial effect on cognition89-92. Although no direct evidence 
for a beneficial effect of this drug on cognitive impairment exists, 
preliminary findings report an association between the use of lithium 
and more preserved cognitive functioning. For instance, Nunes et 
al.93 compared the prevalence of Alzheimer’s disease between a group 
of BD subjects treated chronically with lithium therapy and another 
group of patients without recent lithium therapy. They found that 
lithium-treated BD patients had lower prevalence of Alzheimer’s 
disease and suggested that lithium treatment reduced the prevalence 
of Alzheimer’s disease (AD) in BD patients to levels found in general 
elderly population. In keeping, a recent population-based cohort 
study evaluated dementia risk among BD adults on lithium therapy94. 
Compared with non-use, a year of lithium treatment was associated 
with significantly reduced dementia risk. Moreover, there is prelimi-
nary evidence of improved white matter integrity in BD patients95. 
However, contradictory results exist when evaluating literature on 
cognitive performance in specific domains in subjects under treat-
ment with lithium. Recent studies compared the neuropsychological 
performance of patients treated with and without lithium and found 
significant differences favoring the former96,97. On the other hand, 
prolonged administration of lithium has also been associated with 
discrete negative effects in learning, surveillance, alert and short-term 
memory98. In keeping, a meta-analysis comparing healthy volunteers 
and affective disorder patients reported that lithium had a small, but 
significant, deleterious effect on immediate verbal learning, memory 
and creativity, with no significant effect on other measures99). Taken 
together, this findings point towards a modest, if any, effect of lithium 
on traditional neurocognitive measures. 
On the other hand, there is evidence from healthy subjects, BD 
and other clinical populations suggesting that exposure to different 
psychotropic agents commonly prescribed to bipolar patients is 
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associated with impaired cognition73,100-104. In the same line, obesity 
and metabolic syndrome induced by atypical antipsychotics may 
further influence cognitive functioning105,106. Thus, it is also possible 
that patients responding to lithium treatment are less exposed to 
antipsychotics and better cognitive outcomes are a reflection of that. 
To further support this, studies comparing cognitive performance 
between drug-free BD patients during euthymia and healthy controls 
show less impairment than reported in studies that included treated 
patients. Joffe et al.107 found no differences between drug-free BD 
patients and healthy controls in measures of attention and verbal 
memory. Also, no differences were found when comparing drug-free 
patients with lithium-treated patients. López-Jaramillo et al.108 found 
differences only in measures of verbal, logical and working memory 
while non-medicated patients performed as well as healthy controls 
on other traditional neurocognitive measures. The subgroup of BD 
patients under treatment with lithium performed equally as those 
without pharmacological treatment on all measures. Finally, Torrent 
et al.73 found no differences in neurocognitive performance between 
drug-free BD patients and healthy controls except for one test, the 
TMT-B, which evaluates executive functions. Despite some limita-
tions, like small sample sizes and a possible selection bias of highly 
selected sample of patients with good outcomes, these results point 
towards some sort of iatrogenic-pharmacologic effect of medica-
tion on cognitive performance affecting treated BD patients usually 
included in studies73. 
Taking together findings from drug-free patients and cognitive 
heterogeneity in BD, initially, it should not be assumed that cognitive 
deficits are necessarily present in the course of the disorder. Clini-
cians should rule out potentially treatable causes of these deficits 
such as clinical (i.e., hypothyroidism or metabolic syndrome) or 
psychiatric (i.e., anxiety disorders or abuse/dependence of alcohol) 
comorbidities among patients with clinically significant cognitive 
impairments. Likewise, this subgroup of patients may not be can-
didate for receiving drugs such as benzodiazepines, anticholinergic 
agents or antipsychotics with a negative impact on cognition72,102,109. 
On the other hand, the efficacy of psychosocial interventions may be 
influenced by cognitive status, although this has not been formally 
studied so far. 
In conclusion, cognitive deficits in BD are of paramount impor-
tance as they may represent a bridge between symptomatic remis-
sion and functional recovery that could be targeted by therapeutic 
interventions. They may also constitute a useful tool for predicting 
clinical and functional outcomes to individual patients, a great dif-
ficulty that many clinicians acknowledge when treating subjects 
with BD. Finally, as stated above, cognitive performance and related 
variables should be taken into account at the time of selecting proper 
pharmacological treatment to an individual patient.
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